# clm_61BE04D629BB

subject: Regeneron Pharmaceuticals (/record/regeneron-pharmaceuticals.md)  
predicate: quarterly_research_and_development  
value: 1,271,500,000 United States dollar  
valid_from: 2024-09-30  
valid_to: 2025-03-31  
published: 2024-10-31  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_4BF4BD70527E  
last_updated: 2026-11-08  
cite: AsOf. "Regeneron Pharmaceuticals quarterly research and development: 1,271,500,000 United States dollar", as of 2024-09-30 (until 2025-03-31). Claim clm_61BE04D629BB, https://asof.is/claim/clm_61BE04D629BB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2024, filed 2024-10-31  

## Sources

- https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm (primary, SEC EDGAR 10-Q Q3 FY2024, published 2024-10-31)

## Supersedes

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_research_and_development | 1,200,000,000 United States dollar | valid 2024-06-30 to 2024-09-30 | conf 0.95 | superseded | superseded_by [clm_61BE04D629BB](/claim/clm_61BE04D629BB.md) | [clm_6410B4B55A22](/claim/clm_6410B4B55A22.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.